Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | DRD3 | P35462 | 6/20 | 0.48 |
| ▸ | HTR2A | P28223 | 5/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6816571 | 1.00 | DRD2 (0.48) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL7244244 | 0.91 | DRD2 (0.46) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL7244242 | 0.91 | DRD2 (0.46) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL6816357 | 0.91 | KCNH2 (0.44) | DRD2DRD3HTR2AKCNH2SCN9A | |
| SCHEMBL7175482 | 0.91 | KCNH2 (0.44) | DRD2DRD3HTR2AKCNH2SCN9A | |
| SCHEMBL7239758 | 0.89 | USP30 (0.49) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL5106853 | 0.89 | USP30 (0.49) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL29358671 | 0.89 | USP30 (0.49) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL7239754 | 0.89 | USP30 (0.49) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL3828127 | 0.89 | USP30 (0.49) | DRD2DRD3HTR2AUSP30HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014986-B1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-07-14 | — | — | EP | claimed |
| EP-1021183-B1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | claimed |
| EP-1014985-B1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT 1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2003-05-21 | — | — | EP | claimed |
| US-20010051623-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | US | claimed |
| US-6313118-B1 | HYDROXYTRYPTAMINE RECEPTOR ANTAGONISTS | ASTRA AKTIEBOLAG (SE) | 2001-11-06 | — | — | US | claimed |
| US-6159972-A | Combination of a selective 5-HT1A antagonist and a selective ub. h5-HT.s1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | claimed |
| US-6159970-A | Combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | claimed |
| EP-1014985-A1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT 1B ANTAGONIST OR PARTIAL AGONIST | AstraZeneca AB (SE) | 2000-07-05 | — | — | EP | claimed |
| WO-1999013877-A1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | claimed |
| EP-1014986-B1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-07-14 | — | — | EP | disclosed |
| EP-1021183-B1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1014985-B1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT 1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| US-6534652-B2 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2003-03-18 | — | — | US | disclosed |
| EP-1000048-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| US-6313118-B1 | HYDROXYTRYPTAMINE RECEPTOR ANTAGONISTS | ASTRA AKTIEBOLAG (SE) | 2001-11-06 | — | — | US | disclosed |
| US-6159970-A | Combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | disclosed |
| US-6159972-A | Combination of a selective 5-HT1A antagonist and a selective ub. h5-HT.s1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | disclosed |
| US-6159971-A | Combination of a 5-HT reuptake inhibitor and a h5-HT1B anatagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | disclosed |
| EP-1000048-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | Astra Aktiebolag (SE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005134-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051623-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | HTR1D, HTR1F, HTR2C | DRD2 49/4885DRD3 75/4885HTR2A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.